1Y Close · As of Aug 26, 2026
VIVOZON PHARMACEUTICAL manufactures pharmaceuticals. Pharmaceuticals
Legal name: VIVOZON PHARMACEUTICAL CO., LTD.
In fiscal year 2025, VIVOZON PHARMACEUTICAL (082800) reported revenue of 59.3 billion KRW, down 32.3% from 87.6 billion KRW a year earlier.
Operating profit was -19.2 billion KRW and net income was -32.4 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 174.3 billion KRW, with a P/B of 2.40.
These figures can be verified in the DART filing (receipt no. 20260812000273).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 59.3B | -19.2B | -32.4B |
| 2024 | 87.6B | 2.9B | -10.0B |
| 2023 | 71.3B | 2.6B | -3.4B |
Recent Filings
Officer/Major Shareholder Ownership Report
Officer/Major Shareholder Trading Plan Report
Semi-Annual Report (2026.06)
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Unable to determine due to missing data.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 2 disposal(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-21 | Officer/Major Shareholder Ownership Report |
| 2026-08-19 | Officer/Major Shareholder Trading Plan Report |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-07 | Large Shareholding Report (General) |
| 2026-08-07 | Officer/Major Shareholder Ownership Report |